Literature DB >> 7698535

Historical background and natural history of carcinoids.

W Creutzfeldt1.   

Abstract

Historically, carcinoids are a morphologically distinct class of rare intestinal tumors that behave less aggressively than the more common intestinal adenocarcinomas. Their endocrine nature was recognized much later. Some authors restrict the term carcinoid to intestinal endocrine tumors, and others include a large variety of neuroendocrine tumors. In this review the following definition is given: Carcinoids are tumors of the diffuse endocrine system which are either benign or neoplasms with a more favorable prognosis than carcinomas; they are characterized by a typical growth pattern, silver affinity and positive immunohistochemical reaction with neuron-specific markers, and can express different peptides and biogenic amines. Neuroendocrine tumors originating from the endocrine glands (pituitary, thyroid, adrenals, pancreas) are excluded from the carcinoid group of neoplasms and therefore are highly malignant neuroendocrine carcinomas. For the natural history of carcinoid tumors, several independent predictive parameters can be defined: size, site of origin, growth pattern, and hormone dependence. The number of neuropeptides and amines expressed by a carcinoid or the amount of biologically active neurohormones secreted (and eventually producing a clinical syndrome) are of no prognostic significance regarding malignancy. Only the association of an endocrine tumor with an inappropriate endocrine syndrome seems to be predictive of malignancy.

Entities:  

Mesh:

Year:  1994        PMID: 7698535     DOI: 10.1159/000201195

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  3 in total

Review 1.  Carcinoid tumours.

Authors:  S Janmohamed; S R Bloom
Journal:  Postgrad Med J       Date:  1997-04       Impact factor: 2.401

2.  Requiem for the term 'carcinoid tumour' in the gastrointestinal tract?

Authors:  Runjan Chetty
Journal:  Can J Gastroenterol       Date:  2008-04       Impact factor: 3.522

3.  Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group.

Authors:  Keith Stuart; Donna E Levy; Tom Anderson; Constantine A Axiotis; Janice P Dutcher; Andrew Eisenberg; John K Erban; Al Bowen Benson III
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.